Patent “March-In” As Price Control Draw Little Support At US National Academies Meeting

The use of patent “march-in” rights as a tool to control the price of drugs developed with US federal funding support remains substantially less popular with the government-funded research community than with politicians.

Birch Bayh meeting with Bob Dole | Robert and Elizabeth Dole Archive and Special Collections
March-in rights are based on 1980 legislation authored by Sens. Birch Bayh (r) and Robert Dole (l). • Source: Robert J. Dole Archive and Special Collections, The University of Kansas

A National Academies of Science, Engineering and Medicine workshop focusing on the US National Institutes of Health’s role in drug development and its “impact on access” sounded like it might be a starting point to develop data and potential metrics to build a framework to enable assertion of “march-in” rights on high priced drugs.

When NASEM set the workshop for July 24-25, sponsored by the John & Laura Arnold Foundation and entitled “The Role...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access